Statistical analysis was performed applying the SPSS-PC package (Version 25). Probability of < 0.05 was considered statistically significant. The Mann-Whitney U test or the Kruskal-Wallis H test was applied to analysis of the association between ATRX and DAXX protein expression by IHC and clinicopathologic parameters (for 2-tier or 3-tier analyses, respectively). For this analysis, clinicopathologic parameters were grouped as follows: age, ≤ 60 vs. >60 years; effusion site, peritoneal vs. pleural; FIGO stage, III vs. IV; chemotherapy status, pre- vs. post-chemotherapy specimens; residual disease (RD) volume, 0 cm vs. ≤ 1 cm vs. > 1 cm; response to chemotherapy, complete response vs. partial response/stable disease/progressive disease. Progression-free survival (PFS) and OS were calculated from the date of the last chemotherapy treatment/diagnosis to the date of recurrence/death or last follow-up, respectively. Univariate survival analyses of PFS and OS were executed using the Kaplan-Meier method and log-rank test. Multivariate survival analysis was executed using the Cox Regression Model. Platinum resistance was defined as PFS ≤ 6 months according to guidelines published by the Gynecologic Oncology Group (GOG) and progressive disease or recurrence was evaluated by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Spss pc package
Manufactured by IBM
Sourced in United States
The SPSS-PC package is a comprehensive statistical software solution designed for personal computers. It provides a wide range of data analysis and management tools for researchers, analysts, and professionals. The core function of the SPSS-PC package is to enable users to perform advanced statistical analysis, data manipulation, and reporting on their data.
Automatically generated - may contain errors
Lab products found in correlation
7 protocols using spss pc package
1
Clinicopathologic Factors and Survival in Ovarian Cancer
2
Placental Tissue Biochemical Analysis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The data were analyzed using SPSS/PC+ package (Version 20.0, Chicago, IL). Values are expressed as mean ± SD. The statistical analysis was carried out on placentae of eight dams per group. The placental tissue of each dam in each group was used for the various biochemical and molecular estimations. The actual number of animals per group is indicated for each of the parameters analyzed in the respective table and figures. The treatment groups were compared with the control group by ANOVA and the post hoc least significant difference test.
3
Litter-Based Statistical Analysis of Treatment Effects
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Litter means were used as the unit of analysis. Results are presented as mean ± SD (standard deviation). The data was analyzed using SPSS/PC+ package (Version 20.0, Chicago IL). The treatment groups were compared with the control group by ANOVA and the post-hoc least significant difference test. Data was normalized by using log transformation.
4
Comparative Statistical Analysis of Biological Data
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Results are presented as mean ± standard error (SE). All the statistical analyses were performed using SPSS PC+ package (Version 20, Chicago, IL, USA). The data were checked for normal distribution by testing for skewness. Skewed variables were transformed to normality using log to the base 10 transformation. Statistical differences between means in different groups were determined using one-way analysis of variance (ANOVA) test followed by post hoc Bonferonni multiple correction test. Mean values of various parameters from each group at D15 were compared with those at D30 using Student’s t test. P ≤ 0.05 was considered statistically significant.
5
Comparative Analysis of Biochemical Markers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Values were expressed as mean ± SD. In the present study, statistical analyses were performed using one-way analysis of variance (ANOVA), followed by Fisher's LSD test using SPSS/PC+ package (version 20.0 Chicago IL) for windows. A p value less than 0.05 was considered as a statistically significant difference.
6
Kaplan-Meier Survival Analysis Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Statistical analysis was performed applying the SPSS-PC package (Version 29). Probability of < 0.05 was considered statistically significant.
For progression-free survival (PFS), follow-up time was calculated from the date of last chemotherapy treatment at diagnosis until the date of relapse, date of death from any cause, or end of follow-up. For overall survival (OS), followup time was calculated from the date of diagnosis until date of death from any cause or end of follow-up, whichever occurred first. Survival curves were plotted with the Kaplan-Meier method. The log-rank test was used to compare survival between the groups.
For progression-free survival (PFS), follow-up time was calculated from the date of last chemotherapy treatment at diagnosis until the date of relapse, date of death from any cause, or end of follow-up. For overall survival (OS), followup time was calculated from the date of diagnosis until date of death from any cause or end of follow-up, whichever occurred first. Survival curves were plotted with the Kaplan-Meier method. The log-rank test was used to compare survival between the groups.
7
Palladin Expression in Ovarian Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Statistical analysis was performed applying the SPSS-PC package (Version 26). Probability of <0.05 was considered statistically significant. The Mann-Whitney U test or the Kruskal-Wallis H test was applied to analysis of the association between PALLD mRNA and palladin protein expression by IHC and clinicopathologic parameters (for 2-tier or 3-tier analyses, respectively).
For this analysis, clinicopathologic parameters were grouped as follows: age: ≤60 vs. >60 years; effusion site: peritoneal vs. pleural; FIGO stage: III vs. IV; chemotherapy status: pre-vs. post-chemotherapy specimens; residual disease (RD) volume: 0 cm vs. ≤1 cm vs. >1 cm; response to chemotherapy: complete response vs. partial response/stable disease/progressive disease.
Progression-free survival (PFS) and overall survival (OS) were calculated from the date of the last chemotherapy treatment/diagnosis to the date of recurrence/death or last follow-up, respectively. Univariate survival analyses of PFS and OS were executed using the Kaplan-Meier method and log-rank test. Platinum resistance was defined as PFS≤6 months according to guidelines published by the Gynecologic Oncology Group (GOG) and progressive disease or recurrence was evaluated by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
For this analysis, clinicopathologic parameters were grouped as follows: age: ≤60 vs. >60 years; effusion site: peritoneal vs. pleural; FIGO stage: III vs. IV; chemotherapy status: pre-vs. post-chemotherapy specimens; residual disease (RD) volume: 0 cm vs. ≤1 cm vs. >1 cm; response to chemotherapy: complete response vs. partial response/stable disease/progressive disease.
Progression-free survival (PFS) and overall survival (OS) were calculated from the date of the last chemotherapy treatment/diagnosis to the date of recurrence/death or last follow-up, respectively. Univariate survival analyses of PFS and OS were executed using the Kaplan-Meier method and log-rank test. Platinum resistance was defined as PFS≤6 months according to guidelines published by the Gynecologic Oncology Group (GOG) and progressive disease or recurrence was evaluated by the Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!